February 4, 2019 — Stryker announced Feb. 1, the company is launching a voluntary field action on specific units of the ...
Paragonix Technologies Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) for a design enhancement allowing for the use of the Paragonix SherpaPak Cardiac Transport System (CTS) with small and pediatric donor hearts. Starting in Q1 2019, the system will now be shipped with heart connectors covering most aortic diameters, permitting the anchoring of various size hearts including small pediatric hearts to its proprietary suspension system for improved donor heart transport.
A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts heal themselves – a new model that would reduce the need for bypass surgery, heart transplants or artificial pumping devices.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
February 1, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...
Merit Medical Systems Inc. announced that the PreludeSync Distal Compression Device is now available in the United States, European, Middle Eastern, African and Asia-Pacific markets. The device is the first specifically designed to achieve hemostasis of the radial artery during procedures where access is gained via the distal radial artery.
Cardiovascular Systems Inc. announced that the first patients in the United States were treated using the OrbusNeich Teleport Microcatheter (Teleport), which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Researchers have mapped the active-state structure of the angiotensin II type 1 receptor, the target of widely prescribed drugs to regulate blood pressure and kidney function. The study, published online Jan. 10 in Cell, was conducted by researchers in the Blavatnik Institute at Harvard Medical School and colleagues at Duke University Medical Center.
The higher expense and lower frame rates of 3-D cardiac ultrasound systems have limited their adoption over the past ...
January 31, 2019 — Nearly half (48 percent, 121.5 million in 2016) of all adults in the United States have some type of ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Northwestern Medicine scientists have discovered a novel signaling pathway that promotes healing after a heart attack. The study, published in Cell Metabolism, demonstrates for the first time that the metabolism of dead heart cells by macrophages reprograms the immune cells to launch an anti-inflammatory response and stimulate tissue repair.
Rising temperatures stemming from global climate change may increase the number of infants born with congenital heart defects (CHD) in the U.S. over the next two decades, according to new research in the Journal of the American Heart Association.1 This may also result in as many as 7,000 additional cases over an 11 year-period in eight representative states — Arkansas, Texas, California, Iowa, North Carolina, Georgia, New York and Utah.
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat peripheral ...
The U.S. Food and Drug Administration (FDA) has cleared the Magnetom Lumina 3 Tesla (3T) magnetic resonance imaging (MRI) scanner from Siemens Healthineers.
XableCath Inc., announced that its XableCath blunt and abrasion tip catheters were cleared by the U.S. Food and Drug Administration (FDA) as peripheral crossing catheters. The catheters have been safely and successfully used to cross challenging lesions in both arterial chronic total occlusions (CTOs) and chronic obstructive venous lesions. The recent crossing FDA clearance adds to the previous clearances for endovascular support.